Back to top

ETF News And Commentary

Major U.S. benchmarks ended mostly flat on Thursday following easing concerns about the European Central Bank’s (ECB) bond purchasing volume cut. Investors also remained cautious ahead of today’s non-farm payroll data. Meanwhile, a decline in biotech stocks had a negative impact on the Nasdaq. Among the top ETFs, investors saw (SPY - ETF report) gain nearly 0.1%, while (DIA - ETF report) decreased nearly 0.1% and (QQQ - ETF report) fell about 0.1% on the day.

Two more specialized ETFs are worth noting in particular though as both saw trading volume that was far outside of normal. In fact, in the most recent trading session, both these funds experienced volume levels that were more than double their average. This could make these ETFs the ones to watch out for in the days ahead to see if this trend of extra interest continues:

(FEUZ - ETF report) : Volume 4.83 times average

This Eurozone ETF tracking the NASDAQ AlphaDEX Eurozone Index was in focus yesterday as roughly 3,000 shares moved hands compared with an average of roughly 660 shares. FEUZ gained over 0.3% on the day.

Victor Constancio, Vice President of ECB declined rumours that the volume of quantitative easing program will get reduced. He also said that the bank will continue with its bond purchasing program until it achieves its inflation rate target. These had a positive impact on the ETF. However, in the last one-month period, FEUZ was down about 1%.

(ONEQ - ETF report) : Volume 3.16 times average

This Nasdaq ETF was under the microscope on Thursday as nearly 61,700 shares moved hands. This compares to an average trading volume of 18,880 shares and came as ONEQ lost about 0.3% in the session.

A decline in biotech stocks led the Nasdaq to end in the negative territory yesterday, which in turn dragged this Nasdaq tracking ETF down. iShares Nasdaq Biotechnology (IBB - ETF report) declined 2.3% on the day following a 48.4% plunge in Alnylam Pharmaceuticals’ shares, which announced the termination of testing of its drug, revusiran. However, in the last one-month period, ONEQ was up nearly 0.2%.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>